19599 Investors following Dr Reddys Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Dr Reddy's settles patent litigation with Glaxo
Dr Reddy's Laboratories Ltd has settled the long-pending patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GSK's Imitrex tablets, which is the most prescribed migraine medicine in the US.
Dr Reddy's Laboratories Ltd has settled the long-pending patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GSK's Imitrex tablets, which is the most prescribed migraine medicine in the US.
Announcing the settlement in a press release here on Tuesday, Dr Reddy's said the terms of the settlement remain subject to Government review.
The settlement enables Dr Reddy's to exclusively distribute an authorised generic version of sumatriptan succinate tablets (in the 25 mg, 50 mg and 100 mg strengths) in the US market.
During December 2003, Dr Reddy's had filed abbreviated new drug application (ANDA) for the drug, challenging the patents of the innovator in the US.
Pharma industry observers are viewing the current settlement of Dr Reddy's with GSK as part of the recent trend among the pharma majors to launch authorised generics before their products lose patent protection. Imitrex is one of the big sellers among the GSK's portfolio that is set to lose patent protection.
During December 2003, Dr Reddy's had filed abbreviated new drug application (ANDA) for the drug, challenging the patents of the innovator in the US. 
